Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Clinical Profile and Long-Term Outcomes of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab in a Real-World Setting: High Frequency of Anemia Despite Decreased Intravascular Hemolysis

Katharina Versmold, Ferras Alashkar, Carina Raiser, Richard Ofori-Asenso, Tao Xu, Yutong Liu, Pablo Katz, Aijing Shang, Alexander Roeth

Blood (2021) 138 (Supplement 1): 4314.

https://doi.org/10.1182/blood-2021-147162

Published: 2021

Journal Articles

Real-World Safety of Emicizumab: The First Interim Analysis of the European Haemophilia Safety Surveillance (EUHASS) Database

Aijing Shang, MD PhD, Nives Selak Bienz, Ravi Gadiraju, Tiffany Chang, Peter Kuebler

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-134905

Published: 2020

Journal Articles

Trial in Progress: A Real-World Cohort Study Reporting Patient Profiles, Clinical Outcomes, and Unmet Medical Need of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab in the Essen Center in Germany

Katharina Versmold, Carina Raiser, Imi Faghmous, BS, MSc, MA, MPH, PhD, Pablo Katz, MD, Aijing Shang, MD PhD, Tao Xu, Alexander Röth, MD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-140693

Published: 2020

Journal Articles

Analysis of Hemophilia a Outcomes and Treatment Patterns Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry

Adrienne Lee, MD, Federico Germini, MD MSc, Man-Chiu Poon, MD, Arun Keepanasseril, Quazi Ibrahim, MSc, Aijing Shang, MD PhD, Francis Nissen, Oliver Meier, Cami S. Sima, MD, Davide Matino, Alfonso Iorio, MDPhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-137320

Published: 2020

Journal Articles

COMMODORE Cohort: A Novel, Real-World, Noninterventional Cohort Study Using a Patient-Centered Approach to Evaluate the Safety and Effectiveness of C5 Inhibitors in Patients with Paroxysmal Nocturnal Hemoglobinuria

Aijing Shang, MD PhD, Imi Faghmous, BS, MSc, MA, MPH, PhD, Dan Drozd, MD MSc, Pablo Katz, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-137454

Published: 2020

Journal Articles

Trial in Progress: Quantifying the Humanistic and Socioeconomic Burden of Paroxysmal Nocturnal Hemoglobinuria in the COMMODORE Burden of Illness Study

Roger J Hampton, Pablo Katz, MD, Aijing Shang, MD PhD, Harpal Dhillon, Hayley Hubberstey, PhD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-140679

Published: 2020

Journal Articles

Effect of Moderate and Severe Hemophilia a on Daily Life in Children and Their Caregivers: A CHESS Paediatrics Study Analysis

Kate Khair, PhD, Francis Nissen, Mariabeth Silkey, Tom Burke, Aijing Shang, MD PhD, Martynas Aizenas, Oliver Meier, Jamie O'Hara, MSc, Declan Noone, MSc

Blood (2020) 136 (Supplement 1): 43–45.

https://doi.org/10.1182/blood-2020-134658

Published: 2020

Journal Articles

Treatment Patterns and Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Experience from a Single UK Centre

John Radford, Ellie White, Felipe A. Castro, PhD, Anshuman Chaturvedi, FRCPath, Nathalie Spielewoy, PhD, Adam Gibb, MBBS, Andy Surinach, MPH, Kim Linton, PhD, Aijing Shang, MD PhD, Michael Wenger, MD

Blood (2019) 134 (Supplement_1): 2917.

https://doi.org/10.1182/blood-2019-123664

Published: 2019

Journal Articles

Comparable Overall Survival with Rituximab-Bendamustine (R-Benda) and Rituximab-Gemcitabine-Oxaliplatin (R-GemOx) When Used As Second-Line (2L) Treatment for Diffuse Large B-Cell Lymphoma (DLBCL): A Real-World Study Using US Veterans Health Administration Data

Raluca Ionescu-Ittu, PhD, Aijing Shang, Nancy Vander Velde, Annie Guérin, Yilu Lin, Lizheng Shi, Sherry Shi, Naseer Qayum

Blood (2018) 132 (Supplement 1): 1711.

https://doi.org/10.1182/blood-2018-99-113039

Published: 2018

NARROW

Clinical Profile and Long-Term Outcomes of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab in a Real-World Setting: High Frequency of Anemia Despite Decreased Intravascular Hemolysis

Real-World Safety of Emicizumab: The First Interim Analysis of the European Haemophilia Safety Surveillance (EUHASS) Database

Trial in Progress: A Real-World Cohort Study Reporting Patient Profiles, Clinical Outcomes, and Unmet Medical Need of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab in the Essen Center in Germany

Analysis of Hemophilia a Outcomes and Treatment Patterns Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry

COMMODORE Cohort: A Novel, Real-World, Noninterventional Cohort Study Using a Patient-Centered Approach to Evaluate the Safety and Effectiveness of C5 Inhibitors in Patients with Paroxysmal Nocturnal Hemoglobinuria

Trial in Progress: Quantifying the Humanistic and Socioeconomic Burden of Paroxysmal Nocturnal Hemoglobinuria in the COMMODORE Burden of Illness Study

Effect of Moderate and Severe Hemophilia a on Daily Life in Children and Their Caregivers: A CHESS Paediatrics Study Analysis

Treatment Patterns and Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Experience from a Single UK Centre

Comparable Overall Survival with Rituximab-Bendamustine (R-Benda) and Rituximab-Gemcitabine-Oxaliplatin (R-GemOx) When Used As Second-Line (2L) Treatment for Diffuse Large B-Cell Lymphoma (DLBCL): A Real-World Study Using US Veterans Health Administration Data

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only